Peter Loftus is a reporter at The Wall Street Journal. He covers a range of topics within the healthcare sector, including pharmaceuticals, medical devices, and healthcare technology, with a particular focus on pharmaceutical manufacturing, regulation, and innovations like gene therapy and telehealth. Peter's work has been featured in MarketWatch, LiveMint, Yahoo Finance, Magzter, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Peter Loftus' coverage predominantly focuses on the health and healthcare industry, with a specific emphasis on pharmaceutical companies, drug approvals, shortages, leadership changes within these organizations, and medical devices. His articles often cite data or refer to press releases and government announcements.
Given his focus on the pharmaceutical industry and healthcare sector, he is likely to be interested in pitches related to exclusive insights from experts within these industries regarding new drugs (especially weight-loss drugs and diabetes drugs), company strategies for overcoming shortages or handling leadership changes. Furthermore, offering access to credible data or analysis is crucial when pitching potential topics of interest.
Since Peter's geographic focus is not specified but considering that many of the covered companies are based in the US such as Eli Lilly & Co., Johnson & Johnson among others; relevant sources should have knowledge about these companies' operations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Peter Loftus
Moderna shares were up more than 10% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond Covid-19 vaccines in coming years. The company that gained fame for its messen
By: Peter Loftus
Millions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1.
By: Peter Loftus
The market leader in obesity shots, Lilly hasn’t made a major dent in the pill market yet.
By: Peter Loftus
The market leader in obesity shots, Lilly hasn't made a major dent in the pill market yet.
By: Peter Loftus
Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.
By: Peter Loftus
Peter Loftus U.S. regulators approved a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve.
By: Katherine Hamilton, Peter Loftus
Sales of Pfizer's Comirnaty Covid vaccine dropped 34% in the quarter. - hannah beier/Reuters
By: Katherine Hamilton, Peter Loftus
Pfizer reported better-than-expected second-quarter results, as rising sales of drugs for cancer and heart disease helped offset steep declines for Covid-19 products.
U.S.-traded shares of Novo Nordisk are down more than 6% due to a sales shortfall for its new Wegovy weight-loss pill and a disappointing study outcome for a next-generation weight-loss drug. The stock is under pressure despite the company’s pre-announcement Tuesday of improved results and a boost
By: Anna Wilde Mathews, Peter Loftus
Surging healthcare costs are walloping U.S workers, and they will only worsen next year. For 2027, employers may be facing the biggest health-insurance increase in at least two decades.
